Management of Dyslipidemia after Stroke

Author:

Chang Yoon kyung,Song Tae-Jin

Abstract

Dyslipidemia is a major risk factor for stroke, following hypertension, diabetes, and smoking. Treatment of dyslipidemia is important for the prevention and treatment of various vascular diseases, including stroke, coronary artery disease, and peripheral vascular disease. Statins, ezetimibe, and proprotein convertase subtilisinkexin type 9 (PCSK9) inhibitors have been shown to reduce the risk of stroke and cardiovascular disease in previous studies. When prescribing dyslipidemia drugs for secondary prevention of stroke, the combination, type, and dose of dyslipidemia drugs should be appropriately selected according to the patient's comorbidity and stroke subtype. In the case of statins, highintensity statin administration should be considered, but it is essential to take into account side effects, comorbidities, and individual characteristics of each patient. If the target low density lipoproteincholesterol level is not reached or inappropriate drug dosing due to the side effects of statins, ezetimibe or a PCSK9 inhibitor may be considered. Finally, statin discontinuation due to improper judgment may be detrimental to the patient in the longterm view.

Publisher

Korean Neurological Association

Subject

General Engineering

Cited by 1 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3